SCISPARC

SciSparc said its subsidiary NeuroThera Labs filed a US patent application, published by the US Patent Office, for a combination of MDMA and N‑acylethanolamines, including palmitoylethanolamide, to treat PTSD, anxiety disorders and eating disorders. The application, created in collaboration with Clearmind Medicine, adds to a series of joint patent filings. The publication follows the finalization of an FDA guidance on psychedelic substances that explicitly includes MDMA and provides direction for clinical development and approval requirements. » Plus sur de.investing.com

SciSparc is taking over the patents, trademarks and IP for Xylo’s MUSE endoscopic single‑use system and plans to commercialize the technologies immediately after the transaction closes on March 8, 2026. As consideration SciSparc will issue common shares representing 19.99% of its outstanding capital; alternatively, partly pre‑funded warrants can be used. Target markets are North America, Europe and Latin America, building on existing distribution successes in China; the global market for GERD treatment devices was estimated at about USD 2.5 billion in 2024. The micro‑cap company has recently suffered heavy share price losses, but analysts expect revenue growth and an improvement in profitability this year. » Plus sur de.investing.com

SciSparc reports that its majority-owned company NeuroThera has been granted an Israeli patent for a proprietary combination of opioids and N‑acylethanolamines, including PEA. The patent covers methods and formulations that boost the pain-relieving effect of opioids at lower doses and are intended to reduce side effects such as tolerance, dependence and gastrointestinal complaints. SciSparc holds around 75% of NeuroThera; despite a recent share-price decline, the company has reported strong revenue growth of 188% over the past 12 months and the new patent complements existing protections in Europe, Japan, Australia and Canada. » Plus sur de.investing.com